Advertisement

Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors After Cardiac Surgery: A Review of Current Literature

      There is growing evidence to support the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors for type 2 diabetes mellitus (T2DM) and the management of heart failure. As such, more patients undergoing cardiac surgery are on SGLT2-inhibitor therapy. Despite the numerous benefits of SGLT2 inhibitors on cardiac health, they can be associated with an increased risk of diabetic ketoacidosis, often with normal glucose levels (euglycemic diabetic ketoacidosis or EDKA), which potentially can be detrimental in this vulnerable patient population. In this narrative review, the authors discuss 17 papers that described EDKA in perioperative cardiac surgical patients. The authors discuss suggested preventative measures and management options, with a particular emphasis on raising the clinical awareness of the care teams toward this complication. SGLT2 inhibitor-induced EDKA is a medical emergency that can be difficult to identify in the postcardiac surgical patient due to the overlap of signs and symptoms with other frequent scenarios in these patients. A reduction in SGLT2 inhibitor-associated EDKA can be mitigated by the appropriate perioperative discontinuation of the medication, clinical awareness, and early investigation to diagnose the condition, with emphasis on serum β-hydroxybutyrate. Future quality improvement initiatives are needed to assist in reducing EDKA in patients taking SGLT2 inhibitors in the perioperative surgical setting.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hsia DS
        • Grove O
        • Cefalu WT.
        An update on SGLT2 inhibitors for the treatment of diabetes mellitus.
        Curr Opin Endocrinol Diabetes Obes. 2017; 24: 73-79
        • Buse JB
        • Wexler DJ
        • Tsapas A
        • et al.
        2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetes Care. 2020; 43: 487-933
        • Anker SD
        • Butler J
        • Filippatos G
        • et al.
        Empagliflozin in heart failure with a preserved ejection fraction.
        N Engl J Med. 2021; 385: 1451-1461
        • Lopaschuk GD
        • Verma S.
        Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors.
        JACC Basic Transl Sci. 2020; 5: 632-644
        • Blau JE
        • Tella SH
        • Taylor SI
        • Rother KI.
        Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
        Diabetes Metab Res Rev. 2017; 33https://doi.org/10.1002/dmrr.2924
        • Plewa MC
        • Bryant M
        • King-Thiele R.
        Euglycemic diabetic ketoacidosis.
        StatPearls Publishing, Treasure Island, FL2021
        • Burke KR
        • Schumacher CA
        • Harpe SE.
        SGLT2 inhibitors: A systematic review of diabetic ketoacidosis and related risk factors in the primary literature.
        Pharmacotherapy. 2017; 37: 187-194
        • Goldenberg RM
        • Berard LD
        • Cheng AY
        • et al.
        SGLT2 inhibitor–associated diabetic ketoacidosis: Clinical review and recommendations for prevention and diagnosis.
        Clin Ther. 2016; 38: 2654-2664
        • Totaro RJ
        • Paper RF.
        Epinephrine-induced lactic acidosis following cardiopulmonary bypass.
        Crit Care Med. 1997; 25: 1693-1699
        • Lawton TO
        • Quinn A
        • Fletcher SJ.
        Perioperative metabolic acidosis: The Bradford Anaesthetic Department Acidosis Study.
        J Intensive Care Soc. 2019; 20: 11-17
        • Lipscombe L
        • Booth G
        • Butalia S
        • et al.
        Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: Pharmacologic glycemic management of type 2 diabetes in adults.
        Can J Diabetes. 2018; 42: 88-103
      1. U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: https://www.fda.gov/media/94822/download. Accessed May 29, 2022.

        • Moher D
        • Liberati A
        • Tetzlaff J
        • et al.
        Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.
        PLoS Med. 2009; 6e1000097
        • Tan HLE
        • Acharya S.
        Perioperative cessation of sodium-glucose cotransporter-2 inhibitors: 72 hours or 7 days?.
        Anaesth Intensive Care. 2018; 46: 425
        • Lau A
        • Bruce S
        • Wang E
        • et al.
        Perioperative implications of sodium-glucose cotransporter-2 inhibitors: A case series of euglycemic diabetic ketoacidosis in 3 patients after cardiac surgery.
        Can J Anaesth. 2018; 65: 188-193
        • Osafehinti DA
        • Okoli OJ
        • Karam JG.
        A case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery.
        AACE Clin Case Rep. 2021; 7: 20-22
        • Venkatesh B
        • Moore G
        • Gill D
        • et al.
        Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: 2 cases.
        Crit Care Resusc. 2015; 17: 280-282
        • Kuchay MS
        • Mishra SK
        • Mehta Y.
        Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery.
        Diabetes Metab Syndr. 2021; 15: 909-911
        • Klosko R
        • Rozycki A
        • Lester J.
        Diagnosis and management of SGLT-2 inhibitor-induced euglycemic DKA after cardiac surgery.
        Crit Care Med. 2021; 49: 211
        • Di Palma R
        • Vanderpuye A
        • Satara J
        • et al.
        A case of empagliflozin-induced euglycaemic diabetic ketoacidosis post-off pump coronary artery bypass surgery [abstract]. In: Clinical care and other categories posters: Case reports.
        Diabetic Medicine. 2020; 37: 78
        • Horikoshi R
        • Kitamura T
        • Miyaji K.
        Ketoacidosis related to sodium glucose cotransporter 2 inhibitors after emergency coronary surgery.
        Interact Cardiovasc Thorac Surg. 2019; 29: 323-324
        • Zhang L
        • Tamilia M.
        Euglycemic diabetic ketoacidosis associated with the use of a sodium–glucose cotransporter-2 inhibitor.
        CMAJ. 2018; 190: E766-E768
        • Pontes JP
        • de Melo CS
        • Arantes FB
        • et al.
        Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery.
        J Clin Anesth. 2021; 71110201
        • Chacko B
        • Whitley M
        • Beckmann U
        • et al.
        Postoperative euglycaemic diabetic ketoacidosis associated with sodium–glucose cotransporter-2 inhibitors (gliflozins): A report of 2 cases and review of the literature.
        Anaesth Intensive Care. 2018; 46: 215-219
        • Evans LC
        • Salahuddin S.
        Just sweet enough? A case of euglycaemic ketoacidosis ‘incidentally’ found in a post surgical patient [abstract]. In: Clinical care and other categories posters: Case reports.
        Diabetic Medicine. 2018; 35: 105
        • Smyth CC
        • Collins M
        • McCarthy J
        • et al.
        The catabolic triad: Case report of fasting, major cardiac surgery and sodium–glucose co-transporter 2 inhibitors leading to perioperative euglycaemic ketoacidosis.
        Interact Cardiovasc Thorac Surg. 2021; 33: 494-495
        • Hassanein M
        • Liaqat A
        • Cholin L
        • et al.
        Euglycemic diabetic ketoacidosis post cardiac surgery.
        Am J Kidney Dis. 2020; 75: 584
        • Meyer EJ
        • Gabb G
        • Jesudason D.
        SGLT2 inhibitor–associated euglycemic diabetic ketoacidosis: A South Australian clinical case series and Australian spontaneous adverse event notifications.
        Diabetes Care. 2018; 41: e47-e49
        • Kameda Y
        • Kato M
        • Inoue B
        • et al.
        Euglycemic diabetic ketoacidosis caused by a sodium-glucose cotransporter 2 inhibitor after coronary artery bypass grafting.
        J Am Coll Cardiol. 2019; 73: 2423
      2. Hitchen SA, Lan NS, Ali US, et al. Investigating the effect of an education program on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery [e-pub ahead of print]. Intern Med J. https://doi.org/10.1111/imj.15393. Accessed May 29, 2022.

        • Eberly LA
        • Yang L
        • Nwamaka ED
        • et al.
        Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US.
        JAMA Netw Open. 2021; 4e216139
        • Scheen AJ.
        Evaluating SGLT2 inhibitors for type 2 diabetes: Pharmacokinetic and toxicological considerations.
        Expert Opin Drug Metab Toxicol. 2014; 10: 647-663
        • Halperin I
        • Malcolm J
        • Moore S
        • et al.
        Suggested Canadian standards for perioperative/periprocedure glycemic management in patients with type 1 and type 2 diabetes.
        Can J Diabetes. 2022; 46 (e5): 99-107
        • Zelniker TA
        • Wiviott SD
        • Raz I
        • et al.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet. 2019; 393: 31-39
        • Sulfath TS
        • Amalu K
        • Neema J
        Drug safety alerts by FDA and CDSCO in 2016: A recent Review & A Study Of Its Implementation In Practice.
        Int J Adv Pharm Biotech. 2018; 4: 1-9
      3. Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. Available at: https://www.cpoc.org.uk/guidelines-resources-guidelines-resources/guideline-diabetes. Accessed May 29, 2022.

        • Peters AL
        • Buschur EO
        • Buse JB
        • et al.
        Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium–glucose cotransporter 2 inhibition.
        Diabetes Care. 2015; 38: 1687-1693
        • Peacock SC
        • Lovshin JA.
        Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting.
        Can J Anaesth. 2017; 65: 143-147